Glaukos (GKOS) Financial Analysis & Valuation | Quarter Chart
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outf... more
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the dev... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $10.55B | Exchange | NYSE |
| Sector | Healthcare | Industry | Medical - Devices |
| Country | US | CEO | Thomas William Burns |
| IPO Date | 2015-06-25 | CAGR | 50.82% |
| Employees | 1,094 | Website | www.glaukos.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.03% | Total Yield | 0.03% |
GKOS chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $8.81B | P/E | -208 | Forward P/E | 342.16 | PEG | — |
| P/S | 59.25 | P/B | 52.98 | P/CF | -38047.29 | P/FCF | -2979.69 |
| Sales | $612.84M | Sales 1Y | 41.55% | Sales 3Y | 106.49% | Sales 5Y | 115.69% |
| EPS | $-0.86 | EPS 1Y | 96.97% | EPS 3Y | 23.11% | EPS 5Y | 144.36% |
| Sales QoQ | 23.27% | EPS QoQ | -8.82% | Sales QoQ Avg | 10.81% | EPS QoQ Avg | 154.19% |
| Gross Margin | 79.12% | Operating Margin | -13.13% | Profit Margin | -30.68% | ROCE | -9.84% |
| ROA | -20% | ROE | -27% | Altman Z Score | 26.02 | Piotroski Score | 3 |
| Current Ratio | 5.04 | Quick Ratio | 4.46 | Cash Ratio | 1.12 | Op. CF Ratio | 0.14 |
| Debt/Equity | 0.15 | Debt/Assets | 0.11 | Lt Debt/Equity | 0.15 | Lt Debt/Cap. | 0.13 |
| Intrst Cov. | 306.04 | Inventory Turnover | 2.16 | Asset Turnover | 0.67 | Receivables Turnover | 4.41 |
| Enterprise Value | $8.81B | P/E Ratio | -208 |
| Forward P/E | 342.16 | PEG Ratio | — |
| P/S Ratio | 59.25 | P/B Ratio | 52.98 |
| P/CF Ratio | -38047.29 | P/FCF Ratio | -2979.69 |
| EPS | $-0.86 | EPS Growth 1Y | 96.97% |
| EPS Growth 3Y | 23.11% | EPS Growth 5Y | 144.36% |
| Revenue Growth 1Y | 41.55% | Gross Margin | 79.12% |
| Operating Margin | -13.13% | Profit Margin | -30.68% |
| ROE | -27% | ROA | -20% |
| ROCE | -9.84% | Current Ratio | 5.04 |
| Quick Ratio | 4.46 | Cash Ratio | 1.12 |
| Debt/Equity | 0.15 | Interest Coverage | 306.04 |
| Altman Z Score | 26.02 | Piotroski Score | 3 |
Glaukos (GKOS) valuation & financials
Glaukos (GKOS) has a market capitalization of $10.55B and trades at a price-to-earnings ratio of -208.0. It operates in the Healthcare sector (Medical - Devices).
Glaukos's revenue grew +41.5% over the last year.
Glaukos's next earnings report is scheduled for October 28, 2026 after market close (provider scheduled date); analysts estimate EPS of $-0.10. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)